Consult your doctor before use if you have a history of allergies, kidney problems, or low potassium
And emerging data suggest that optimizing the hormonal environment during the menopausal transition more broadly may positively influence weight loss trajectories and body composition outcomes during GLP-1 treatment [17], consistent with the mechanistic picture of restored hormonal signaling creating a more metabolically receptive physiological state
Eli Lilly submitted the orforglipron NDA to the FDA in Q1 2026 following ATTAIN Phase 3 trial data showing 14.7% body weight reduction at 45mg positioning the worlds first oral small molecule GLP-1 receptor agonist for obesity for anticipated FDA approval in late 2026 or 2027
What Medicares Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries The Centers for Medicare & Medicaid Services (CMS) has released a memo fleshing out the design of a short-term program providing Medicare coverage of GLP-1s for obesity in 2026 ahead of a multi-year demonstration program beginning in 2027
Swissmedic Warning On 26th March 2024, a press release with concerns over Lemon Bottle treatment was issued by the Federal Council of Switzerland based on findings from Swissmedic (the national authority for drugs and medicinal products)
Longevity and anti-aging protocols For general anti-aging applications, the standard 5 mg daily for 20 days, repeated once or twice annually, represents the most validated approach